2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Gastrointestinal
1
Conditions
Febrile Neutropenia
6
Neutropenia
5
Neoplasms
4
Infections
4
Fever
4
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Hematologic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Urinary Tract Infections
1
Stomach Neoplasms
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Recurrence
1
Pulmonary Arterial Hypertension
1
Pseudomonas Infections
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia
1
Pancreatic Neoplasms
1
Interventions
pembrolizumab
300
Nivolumab
273
Ipilimumab
250
aldesleukin
137
Cyclophosphamide
135
Interleukin-2
105
trametinib
82
dabrafenib
76
Temozolomide
75
Dacarbazine
74
Vemurafenib
71
fludarabine
67
fludarabine phosphate
61
Biopsy
49
binimetinib
47
sargramostim
44
Radiosurgery
44
Bevacizumab
43
Paclitaxel
42
encorafenib
40
incomplete Freund's adjuvant
39
atezolizumab
38
Radiotherapy
37
Cisplatin
36
CTLA-4 Antigen
36
Carboplatin
35
cobimetinib
34
Specimen Handling
34
Magnetic Resonance Spectroscopy
34
Introns
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Melanoma
×
Vancomycin
×
Clear all
NCT04208958
2025-10-27
ConsortiumIO
Vedanta Biosciences, Inc.
Phase 1/2
Completed
56 enrolled
11 charts
NCT06540391
2025-09-26
MELODY-1
Microbiotica Ltd
Phase 1
Active not recruiting
41 enrolled